Why did Hanmi get caught in dilemma?

Published: 2016-10-05 10:23:44

Updated: 2016-10-05 10:23:44

Hanmi Pharm gets in the focus of controversy as being associated with the technology export of an antibody of KRW 1 trillion with Genentech while having issues with Boehringer Ingelheim which decided to return the license of ‘olmutinib(Korean product name: Olita)’ and the timing of the announcement.

Among the issues, the most controversy one is the timing of the announcement after getting in...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.